

1 **Seroprevalence of Hospital Staff in Province with Zero COVID-19 Cases**

2 Tanawin Nopsopon, M.D.

3 Lecturer, Department of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok,
4 Thailand

5 tnopsopon@gmail.com

6

7 Krit Pongpirul, M.D., M.P.H., Ph.D. (Corresponding Author)

8 Assistant Professor, Department of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn
9 University, Bangkok, Thailand; Department of International Health, Johns Hopkins Bloomberg School of Public
10 Health, Baltimore, MD, USA; Bumrungrad International Hospital, Bangkok, Thailand

11 doctorkrit@gmail.com

12

13 Korn Chotirosniramit

14 Medical Student, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

15 korn.chotiros@gmail.com

16

17 Wutichai Jakaew, M.D.

18 Chairman of Infectious Control Board, Ranong Hospital, Ranong, Thailand

19 Nooknick_nn@yahoo.com

20

21 Chuenkwan Kaewwijit, B.Sc.

22 Head of Medical Laboratory Department, Ranong Hospital, Ranong, Thailand.

23 chuenkwan@windowslive.com

24

25 Sawan Kanchana, M.D., MFRCPT.

26 Hospital Director, Ranong Hospital, Ranong, Thailand

27 drsawan@me.com

28

29 Narin Hiransuthikul, M.D., Ph.D.

30 Professor, Department of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn University,
31 Bangkok, Thailand

32 narin.h@chula.ac.th

33 Words: 1,939 words (Text), 260 words (Abstract), 1 figure, 2 tables

34

35 **ABSTRACT:**

36 **BACKGROUND.** COVID-19 seroprevalence data has been scarce, especially in less developed countries with a
37 relatively low infection rate.

38 **METHODS.** A locally developed rapid immunoglobulin M (IgM) / immunoglobulin G (IgG) test kit was used for
39 screening hospital staff in Ranong hospital which located in a province with zero COVID-19 prevalence in Thailand
40 from April 17 to May 17, 2020. A total of 844 participants were tested; 82 of which were tested twice with one
41 month apart. (Thai Clinical Trials Registry: TCTR20200426002)

42 **RESULTS.** Overall, 0.8% of the participants (7 of 844) had positive IgM, none had positive IgG. Female staff
43 seemed to have higher IgM seropositive than male staff (1.0% vs. 0.5%). None of the participants with a history of
44 travel to the high-risk area or a history of close contact with PCR-confirmed COVID-19 case had developed
45 antibodies against SARS-CoV-2. Among 844 staff, 811 had no symptom and six of them developed IgM
46 seropositive (0.7%) while 33 had minor symptoms and only one of them developed IgM seropositive (3.0%). No
47 association between IgM antibody against SARS-CoV-2 status and gender, history of travel to a high-risk area,
48 history of close contact with PCR-confirmed COVID-19 case, history of close contact with suspected COVID-19
49 case, presence of symptoms within 14 days, or previous PCR status was found. None of the hospital staff developed
50 IgG against SARS-CoV-2.

51 **CONCLUSION.** COVID-19 antibody test could detect a substantial number of hospital staffs who could be
52 potential silent spreaders in a province with zero COVID-19 cases. Antibody testing should be encouraged for mass
53 screening, especially in asymptomatic healthcare workers.

54 **TRIAL REGISTRATION.** This study was approved by the Institutional Review Board of Chulalongkorn
55 University (IRB No.236/63) and the Institutional Review Board of Ranong Hospital. (Thai Clinical Trials Registry:
56 TCTR20200426002)

57 **FUNDING.** None.

58

59

60 **Introduction**

61 Seroprevalence data has been scarce in Asian countries besides China. Along with the gold-standard polymerase
62 chain reaction (PCR) testing, antibody testing is beneficial for epidemiological investigation and epidemic control of
63 infectious diseases including the present coronavirus disease 2019 (COVID-19). In Singapore, serological evidence
64 was used to trace and identify missing spreader for three clusters (1). Asymptomatic silent spreaders have been of
65 major concern as suggested by a systematic review—could be as low as 1.6% of COVID-19 confirmed cases in
66 China or as high as 51.7% of confirmed cases in Diamond Princess cruise (2).

67 Early COVID-19 prevalence studies were based only on PCR for the diagnosis of severe acute respiratory
68 syndrome coronavirus 2 (SARS-CoV-2) infection in individuals. However, recent studies tended to report PCR
69 along with serological test results. Our rapid systematic review of peer-reviewed evidence up to May 1, 2020,
70 reported a range of seroprevalence among healthcare workers from 2.0% in Lebanon and Claremont, the USA to
71 4.5% in Padova, Italy (3). China reported an overall seroprevalence of 2.5% in a hospital setting, in which 1.8% and
72 3.5% were among healthcare workers and asymptomatic patients, respectively (4). Additionally, China studied the
73 development of antibodies against SARS-CoV-2 in symptomatic confirmed COVID-19 cases and found that
74 immunoglobulin M (IgM) reached its peak 20–22 days after onset while immunoglobulin G (IgG) reached its peak
75 17–19 days after onset (5). Some works emphasized on antibody testing for hospital workforce and policy issues.
76 Another seroprevalence study in Belgium conducted on healthcare personnel who worked in a tertiary hospital
77 found 6.4% seroprevalence and identified some risk factors for developing antibodies against SARS-CoV-2 (6).

78 More recent studies in the medRxiv preprint repository reported a range of seroprevalence in healthcare
79 personnel from 0% (7) to 45.3% (8) with intra-regional variations. In China, for example, seroprevalence among
80 hospital staff ranged from 1.8% (4) to 17.1% (9) whereas seroprevalence of healthcare workers in Asia besides
81 China ranged from 3.3% (10) to 5.4% (11). In Southeast Asia, there was only a study from Thailand reported a 3.7%
82 seroprevalence (12). Seroprevalences in healthcare personnel varied from 1.1% (13) to 45.3% in Europe (8) and
83 from 2% (3) to 7.6% (14) in North America. Only one African study reported zero seroprevalences in hospital staff
84 in Libya (7) whereas no seroprevalence studies were from South America, Antarctica, or Australia.

85 Ideally, both PCR and antibody testing provided complementing information to shape the picture of the
86 situation in a specific hospital, area, or country. However, most low- to middle-income countries could not afford

87 the cost of laboratory tests and had to develop criteria-based policies for resource-use optimization. In Thailand, for
88 instance, the PCR is reserved for individuals who meet the national criteria for COVID-19 polymerase chain
89 reaction testing.

90 Ranong is one of 77 provinces in Thailand with zero cumulative confirmed COVID-19 case from April 17
91 to May 17, 2020, and still had no case as of July 4, 2020 (Figure 1). Hospital is one of the highest risk areas for
92 receiving and spreading pathogens—healthcare workers developed a higher chance of getting infected by co-
93 workers or patients and vice versa. This study aims to estimate the hospital-wide seroprevalence in healthcare
94 workers who worked in the largest public hospital in Ranong to develop the strategies to slow down the pandemic
95 and ensure the safety of healthcare workers who come to work and patients who visit the hospital.

96 **Results**

97 *Healthcare workers' demographics.* All 844 Thai hospital staff were invited to participate in the study and tested for
98 IgM and IgG antibodies against SARS-CoV-2 (100% participation rate). Their median age was 42 years
99 (interquartile range 32–50). Most of them (71.7%) were female and 96.1% had no symptoms. The 33 symptomatic
100 participants (3.9%) reported cough (1.7%), rhinitis (1.5%), sore throat (1.4%), dyspnea (0.5%), and fever (0.2%).
101 History of travel to the high-risk area was 2.5%, history of close contact PCR confirmed COVID-19 case was 2.0%,
102 history of close contact suspected case was 38.1%. Only 1% of participants had previous negative PCR results while
103 the rest never get tested (Table 1).

104 (insert Table 1 about here)

105 *Serological results of healthcare workers in Ranong hospital.* Overall, seven hospital staff tested positive for
106 COVID-19 IgM (0.8%, 95% CI: 0.4%, 1.7%) while none of the participants developed IgG. Female staff seemed to
107 have higher rate of positive IgM (1.0%, 95% CI: 0.5%, 2.1%) than male (0.5%, 95% CI: 0.1%, 2.6%). None of the
108 participants with a history of travel to the high-risk area or a history of close contact with PCR-confirmed COVID-
109 19 case developed antibodies against SARS-CoV-2. There was no statistical difference in IgM seroprevalence
110 between staff with and without a history of close contact with suspected COVID-19 case. Among 844 staff, 811 had
111 no symptom and six of them developed IgM seropositive (0.7%, 95% CI: 0.3%, 1.6%) while 33 had minor
112 symptoms and only one of them developed immunoglobulin M (3.0%, 95% CI: 0.5%, 15.3%). Of 12 staff with sore

113 throat, one had positive IgM (8.3%, 95%CI: 1.5%, 35.4%). There was zero IgM seroprevalence in staff with fever,
114 cough, rhinitis, or dyspnea. Of 844 participants, eight had previous negative PCR result and none has developed the
115 antibody for SARS-CoV-2 (Table 1). No association between IgM antibody against SARS-CoV-2 status and gender,
116 history of travel to a high-risk area, history of close contact with PCR-confirmed COVID-19 case, history of close
117 contact with suspected COVID-19 case, presence of symptoms within 14 days, or previous PCR status was found.
118 None of the hospital staff developed IgG against SARS-CoV-2.

119 *Characteristics of seropositive participants.* Seven participants developed IgM antibody in May. Their age ranged
120 from 20 to 49 years. Six of them were female while only one staff was male. All of them were Thai, had no history
121 of travel to a high-risk area, no history of contact with PCR-confirmed COVID-19 case, and no previous PCR status.
122 Three had a history of contact with suspected COVID-19 case while the other three did not. Participant 7 was only
123 one with IgM positive who had a symptom (i.e. sore throat) within 14 days before antibody testing. Nasopharyngeal
124 swabs of all seven staff with a positive antibody tested negative for SARS-CoV-2 on PCR (Table 2).

125 (insert Table 2 about here)

126 *Repeating antibody tests in random sampling participants.* Of 844 participants, 100 were randomly selected to get
127 repeating antibody testing in April and May. None of them had any immunoglobulin developed in April whereas 82
128 also participated in antibody testing in May which showed no antibody against COVID-19.

129 **Discussion**

130 In a small seaside province, Ranong, which had 193,370 inhabitants, located in the south of Thailand closed to the
131 Andaman Sea and had border close to Myanmar, there was zero officially PCR-confirmed COVID-19 case
132 compared to the current situation in Thailand (0.048 per thousand). This zero prevalence could be either from good
133 compliance to public health recommendations or a low number of individuals who get PCR testing due to the
134 stringent national criteria.

135 In this study, we reported a 0.8% IgM seroprevalence in Ranong hospital staff while their PCR tests were
136 negative. While critics might argue that the antibody test had a high false-positive rate, especially in a population
137 with high pre-test probability such as hospital staff, the PCR test could have a high false-negative rate, especially
138 without a highly sensitive diagnostic test (15).

139 Of seven seropositive hospital staff, only one was symptomatic and none of them had a history of travel to
140 high-risk area or history of close contact with PCR-confirmed COVID-19 case. The current national criteria and
141 policies for PCR testing mostly rely on risk histories and symptoms so asymptomatic individuals or those with
142 minor symptoms were left out, resulting in an underestimation of the actual prevalence of COVID-19.

143 Our study reported a lower seroprevalence in healthcare workers than hospitals in China (0.8% vs. 1.8%)
144 (4), a tertiary hospital in Belgium (0.8% vs. 6.4%) (6), and a rural hospital located in low COVID-19 prevalence
145 county of Germany (0.8% vs 2.7%) (16). Unlike China, Belgium, and Germany where the seroprevalences were
146 mostly from positive IgG, our study revealed mostly positive IgM. Comparison with Belgium and Germany hospital
147 should be interpreted with caution due to the unknown PCR status of subjects of the two studies.

148 COVID-19-confirmed patients developed peak IgM at 20–22 days and peak IgG at 17–19 days after
149 symptom onset (5). For patients with no or minor symptoms, the onset might not be possible to determine. In this
150 study, we used a qualitative antibody test kit so the relatively lower antibody level in early infected persons might
151 not be detectable. Repeating PCR or quantitative antibody tests for suspected individuals was practiced in many
152 countries. However, the cost would be doubled or more and might not be possible for low- or middle-income
153 countries. We attempted to repeat the antibody test in randomly selected participants; however, only 82 of them
154 could participate in the follow-up test and none of them developed antibodies against SARS-CoV-2 in both first and
155 second tests. Rapid antibody tests should be more affordable to permit multiple tests among high-risk asymptomatic
156 individuals who could be silent spreaders.

157 Serological testing provides some crucial epidemiological information and would have been more effective
158 when combined with other diagnostic tests such as PCR. With immunoglobulin status and PCR results, we can
159 shape the situation more precisely for both individual and regional views. Hopefully, with this and other vigorous
160 and dedicated studies on antibody status around the globe, antibody testing would provide useful information for
161 pandemic control.

162 In conclusion, the COVID-19 antibody test could detect a substantial number of hospital staffs who could
163 be potential silent spreaders in areas with zero COVID-19 case. Antibody testing should be encouraged for mass
164 screening, especially in asymptomatic healthcare workers.

165 **Methods**

166 **Participants**

167 All 844 healthcare workers including the physician, nurse, medical assistance, medical technician, and non-medical
168 officers of the largest public hospital in Ranong province that reported zero cumulative PCR-confirmed COVID-19
169 cases during the entire study period (April 17 to May 17, 2020), were invited to participate in this study. All of them
170 accepted to participate with written informed consent. Participants with active symptoms suiting national criteria for
171 polymerase chain reaction testing were quarantined and excluded. Participants were asked to answer a survey about
172 risk history for COVID-19, recent symptoms in the past two weeks, and previous PCR tests if available.

173 **Antibody testing**

174 Locally developed Baiya Rapid IgG/IgM test kit (Baiya Phytopharm, Thailand) which reported the presence of IgM
175 and IgG qualitatively, was used for antibody testing in this study. The internal validation of the test kit using the
176 serum of 51 PCR confirmed COVID-19 cases and 150 controls showed sensitivity 94.1% (48 of 51) and specificity
177 98.0% (147 of 150) of IgM or IgG antibody. Participants with positive IgM were encouraged to have PCR test if
178 available.

179 **Study procedures**

180 On April 17, 2020, of 844 participants, 100 were randomly selected to have their first antibody testing. On May 17,
181 2020, all the remaining participants were tested for serological immunity whereas the 100 healthcare workers who
182 tested in April had their second antibody testing.

183 **Statistics**

184 Categorical data were presented with counts and percentages while continuous data were reported with median and
185 interquartile range. Association between categorical variables and the status of immunoglobulin was analyzed using
186 Fisher's exact test. The 95% confidence interval (CI) of the seroprevalence was calculated by Wilson's method
187 using binomial probabilities. Missing data were excluded. All data were analyzed using Stata 16.1 (College Station,
188 TX).

189

190 **Study approval**

191 This study was approved by the Institutional Review Board of Chulalongkorn University (IRB No.236/63) and the
192 Institutional Review Board of Ranong Hospital. (Thai Clinical Trials Registry: TCTR20200426002)

193 **Author Contributions**

194 TN, KP, and NH conceptualized the study, designed methodology, and administrated the project. TN, KC, KP, WJ,
195 CK and SK contributed to data curation and clinical investigation. TN, KC, and KP validated the data. TN and KP
196 performed formal analysis and provided software. TN visualized the data. KP, WJ, SK, NH provided resources for
197 the study. KP, SK, and NH supervised the study. TN and KP wrote the original draft of the manuscript. All authors
198 reviewed and edited the final manuscript.

199 **Acknowledgements**

200 We thank Baiya Phytopharm, Thailand for supporting the Baiya Rapid COVID-19 IgG/IgM test kit. The company
201 did not involve in the data analysis, interpretation, or manuscript preparation.

202

203 **References**

- 204 1. Yong S, Anderson D, Wei W, Pang J, Chia W, Tan C, et al. Connecting clusters of COVID-19: an
205 epidemiological and serological investigation. *Lancet Infect Dis.* 2020;20(7):809-15.
- 206 2. Gao Z, Xu Y, Sun C, Wang X, Guo Y, Qiu S, et al. A Systematic Review of Asymptomatic Infections with
207 COVID-19. *J Microbiol Immunol Infect.* 2020.
- 208 3. Bobrovitz N, Arora R, Yan T, Rahim H, Duarte N, Boucher E, et al. Lessons from a rapid systematic review of
209 early SARS-CoV-2 serosurveys. *medRxiv.* 2020:2020.05.10.20097451.
- 210 4. Xu X, Sun J, Nie S, Li H, Kong Y, Liang M, et al. Seroprevalence of immunoglobulin M and G antibodies
211 against SARS-CoV-2 in China. *Nat Med.* 2020.
- 212 5. Long Q, Liu B, Deng H, Wu G, Deng K, Chen Y, et al. Antibody responses to SARS-CoV-2 in patients with
213 COVID-19. *Nat Med.* 2020;26(6):845-8.
- 214 6. Stensels D, Oris E, Coninx L, Nuyens D, Delforge M, Vermeersch P, et al. Hospital-Wide SARS-CoV-2
215 Antibody Screening in 3056 Staff in a Tertiary Center in Belgium. *Jama.* 2020.
- 216 7. Kammon A, El-Arabi A, Erhouma E, Mehemed T, and Mohamen O. Seroprevalence of antibodies against
217 SARS-CoV-2 among public community and health-care workers in Alzintan City of Libya. *medRxiv.*
218 2020:2020.05.25.20109470.
- 219 8. Houlihan C, Vora N, Byrne T, Lewer D, Heaney J, Moore D, et al. SARS-CoV-2 virus and antibodies in front-
220 line Health Care Workers in an acute hospital in London: preliminary results from a longitudinal study.
221 *medRxiv.* 2020:2020.06.08.20120584.
- 222 9. Chen Y, Tong X, Wang J, Huang W, Yin S, Huang R, et al. High SARS-CoV-2 antibody prevalence among
223 healthcare workers exposed to COVID-19 patients. *J Infect.* 2020.
- 224 10. Nakamura A, Sato R, Ando S, Oana N, Nozaki E, Endo H, et al. Seroprevalence of Antibodies to SARS-CoV-2
225 in Healthcare Workers in Non-epidemic Region: A Hospital Report in Iwate Prefecture, Japan. *medRxiv.*
226 2020:2020.06.15.20132316.
- 227 11. Fujita K, Kada S, Kanai O, Hata H, Odagaki T, Satoh-Asahara N, et al. Quantitative SARS-CoV-2 antibody
228 screening of healthcare workers in the southern part of Kyoto city during the COVID-19 peri-pandemic period
229 *medRxiv.* 2020:2020.05.12.20098962.

- 230 12. Nopsopon T, Pongpirul K, Chotirosniramit K, and Hiransuthikul N. COVID-19 Antibody in Thai Community
231 Hospitals *medRxiv*. 2020:2020.06.24.20139188.
- 232 13. Psychogiou M, Karabinis A, Pavlopoulou I, Basoulis D, Petsios K, Roussos S, et al. Antibodies against SARS-
233 CoV-2 among health care workers in a country with low burden of COVID-19. *medRxiv*.
234 2020:2020.06.23.20137620.
- 235 14. Stubblefield W, Talbot H, Feldstein L, Tenforde M, Rasheed M, Mills L, et al. Seroprevalence of SARS-CoV-2
236 Among Frontline Healthcare Personnel During the First Month of Caring for COVID-19 Patients - Nashville,
237 Tennessee. *Clin Infect Dis*. 2020.
- 238 15. Woloshin S, Patel N, and Kesselheim A. False Negative Tests for SARS-CoV-2 Infection - Challenges and
239 Implications. *N Engl J Med*. 2020.
- 240 16. Schmidt S, Grüter L, Boltzmann M, and Rollnik J. Prevalence of serum IgG antibodies against SARS-CoV-2
241 among clinic staff. *PLoS One*. 2020;15(6):e0235417.
- 242




Figure 1. Numbers of Confirmed COVID-19 Cases across Geographical Areas of Thailand as of July 4, 2020. Bangkok Metropolitan had the most cumulative confirmed COVID-19 cases, 1,609 cases, while Ranong, the province of focus in this study, had no confirmed COVID-19 case.